CIPLA Cipla Ltd Other Situations Announcement 2025 - USFDA Approval Cipla Ltd. received USFDA approval for Nilotinib Capsules (50, 150, and 200 mg) on February 19, 2025, and plans to launch the product in FY 2025-26 for treating chronic myeloid leukemia..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Cipla Ltd